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Metal-targeting drugs are being widely explored as a possible treatment of Alzheimer’s disease, but most of 
these ligands are developed to coordinate Cu(II). In a previous communication (Metallomics, 2015, 7, 1229) 
we have shown another strategy where Cu(I) was targeted with the PTA (1,3,5-triaza-7-phosphaadamantane) 
ligand that is in addition able to target Cu(II) as well, reduce it and keep it in a safe complexed species. Removal 
of Cu(II) from the amyloid-β peptide prevents the stabilization of oligomers and protofibrils and the 
complexation of Cu(I) also stops the formation of reactive oxygen species. Besides, the presence of zinc, which 
is found in the synaptic cleft in higher concentration than copper, can hamper the ability of metal-targeting 
drug candidates, an issue that is still poorly considered and studied. Here we show that PTA fully keeps the 
above described properties even in presence of zinc, thus fulfilling an additional pre-requisite for its use as a 
model of Cu(I)-targetting drug candidates in the Alzheimer’s disease context. 
Introduction 
Alzheimer's disease (AD) is the leading cause of dementia in the elderly affecting nearly 47 million 
people worldwide.1 The underlying mechanisms of this complex disorder are not clear, but there is 
evidence and a relatively wide agreement that the so-called amyloid cascade is a key and early event 
in the development of AD. This hypothesis proposes an increased extracellular accumulation of the 
peptide amyloid-β (Aβ) and subsequent aggregation into fibrils found in amyloid plaques, a post-
mortem hallmark of AD.2 The mis-metabolism of Aβ has been suggested to be the initiating event in 
AD pathogenesis. Formation of Aβ aggregates would instigate further pathological events, including 
the formation of intracellular neurofibrillary tangles of Tau protein (the other hallmark of AD), 
disruption of synaptic connections and ultimately neuronal cells death and dementia. 
In vitro and in vivo studies indicate that metal ions, mainly Cu, Zn and Fe ions are involved in AD.3,4 In 
particular, the concentration of metal ions in the senile plaques is higher than in cerebrospinal fluid 
(mM versus µM).5 There is even evidence that the binding of metal ions to Aβ is required for 
aggregation at physiological concentrations.6 Cu and Zn ions can both bind to Aβ,7 while there is no 
strong evidence of Fe binding to Aβ.3,8 Cu and Zn modulate Aβ aggregation both with respect to the 
kinetics and mechanisms of aggregation and the morphology of the formed aggregates.9,10 Based on 
in vitro experiments, it has been proposed that Cu can stabilize metastable oligomeric species 
considered as the most toxic ones,11–13 while Zn induces the formation of weakly-structured 
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aggregates.13–18 However, results from in vitro experiments also mainly depend on the ratio of metal 
ions per peptide, a parameter that is not fully known under AD conditions.7,18 Due to its redox ability, 
Cu ions participate in the formation of Reactive Oxygen Species (ROS) contributing to the oxidative 
stress implicated in AD.19 Therefore disrupting the extracellular Aβ/Cu interaction and restoring the 
Cu homeostasis using synthetic ligands remains a promising therapeutic strategy.20 When Cu is 
regarded as the therapeutic target, Cu(II) has been preferred over Cu(I) although the extra-cellular 
space in brain is reductive (the ascorbate concentration in the extracellular fluid in the brain is 
estimated between 200 and 400 µM), 21,22 and the ability of the Amyloid Precursor Protein to reduce 
the Cu(II).23  
Cu dysmetabolism was also reported in other neurological diseases like prion diseases, motor neuron 
diseases and Parkinson’s disease.24–25 Cu is an essential metal ion26 and, in the case of neurons, this 
is strengthened by the fact that neurological disturbances are hallmarks of the congenital diseases of 
Cu metabolism, such Menkes’ (accumulation of Cu) and Wilson’s (lack of Cu).27 Furthermore, it was 
found that, when in the synaptic cleft, Cu can control the activity of neurotransmitter receptors, thus 
affecting excitability. These aspects reinforce the importance of the maintenance of Cu homeostasis 
for nervous system physiology.28 
Cu(I/II) and/or Zn(II) do bind to the Aβ peptide, with the following properties (figure 1): (i) Two Cu(II)-
Aβ species coexist near physiological pH with a main component (noted I) where Cu(II) is bound by the 
N-terminal amine, the adjacent carbonyl function and two imidazole rings from His6 and His13 or 
His14. In the minor component (noted II), the Asp1-Ala2 peptide bond is deprotonated and bound to 
the Cu(II). This induces the coordination of the adjacent carbonyl function. The last equatorial position 
is occupied by an imidazole ring from one of the three His residues, with no strong preference for one 
His residue.4,7 The most consensual value for the conditional affinity of Cu(II) to Aβ is 1010 M-1 at pH 
7.4.29,30 (ii) Regarding Zn, the coordination is made by two His and two carboxylic acid residues, with a 
main contribution from His6 and Glu11 and is the predominant species around pH 7.4.7,31 Conditional 
affinity is about 4 to 5 orders of magnitude weaker compared to Cu(II) at pH 7.4.32 (iii) Cu(I) is bound 
by imidazole rings from two among the three His residues in a linear disposition.3,33,34 The affinity for 
Cu(I) is still controversial, with values between 107 M-1 and 1010 M-1 reported in the literature.30,35,36 (iv)  
hetero-bimetallic species have also been observed and spectroscopically characterized. For CuII,Zn(Aβ), 
Figure 1. Proposed Cu(II) (upper), Cu(I) (bottom left) and Zn(II) (bottom right) coordination to Aβ at 
physiological pH. Values of % of Cu(II) are given from ref. 6. 
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the co-presence of Zn induces a shift of Cu(II) towards the component II site, while Zn may keep two 
imidazole rings from the remaining His and two carboxylates. For CuI,Zn(Aβ), the Cu(I) site is identical 
as in absence of Zn (figure 1), and the Zn site may accordingly change significantly with the possibility 
to keep only one imidazole ring from His.37,38 Given the different coordination geometries of Cu(II) and 
Cu(I) bound to the peptide, the redox properties of the Cu(Aβ) species are every complex. The electron 
transfer is sluggish, proceeding via a low populated highly redox-active state in equilibrium with the 
two Cu(I)(Aβ) and Cu(II)(Aβ) spectroscopically characterized.39 This so-called “in-between” state is also 
responsible of the production of ROS.40 
 
Despite all the broad research undergone on the bioinorganic aspect of Alzheimer’s disease in the last 
years, there is still no clear evidence of the in vivo metal-binding to Aβ beyond its presence in 
aggregates.4,41 Nevertheless, the metal hypothesis in link to the amyloid cascade proposes that weakly-
bound metal ions from extracellular pools, especuially those released in the synaptic cleft, could 
interact with Aβ peptide.25,42 From this interaction, a modulation of the aggregation of the peptide and 
a redox activity of the Cu-peptide complex have been hypothesised with different degrees of 
implication in the development of Alzheimer’s disease. 
Different strategies have been considered and studied for the treatment of AD, many of them focussed 
in the amyloid cascade hypothesis and its implication on the development of the disease. Given the 
potential impact of metal ions in AD the production of metal-coordinating ligands, and more 
specifically Cu-targeting molecules can be found among these strategies.20 Two examples of these 
molecules are clioquinol and PBT2, ligands that made up to Phase II clinical trials but failed in this 
step.43 Current attempts at regulating Cu levels in AD might not have been successful for several 
reasons: (i) keeping Cu(II) as the sole target and (ii) the poor selectivity between Cu and Zn of the 
proposed molecules given that Zn concentration within the synaptic clefts where the amyloid cascade 
occurs is much higher than Cu: up to 350 µM for zinc44 and in the 10-100 µM range for copper.45,46 With 
respect to Cu(I), reaching an appropriate Cu(I) over Zn(II) selectivity mainly relies on the nature of the 
ligand (rather than on geometrical constraints as for Cu(II)). Since Cu(I) is a softer acid than Zn(II) 
according to the HSAB theory,47 softer base ligands such as S and P ligands will prefer Cu(I) over Zn(II) 
binding. Hence, the PTA (PTA = 1,3,5-triaza-7-phosphaadamantane) ligand previously studied for its 
ability to remove either Cu(I) or Cu(II) (after reduction) from Aβ and stop associated ROS formation 
and prevent Cu(II) modulation of Aβ aggregation,48 should fulfil this selectivity requirement. 
PTA is a cage-like water-soluble air-stable monodentate phosphine ligand with properties suitable for 
medicinal applications, especially the ability to solubilize transition metal complexes with anti-tumour 
activity.49 Since PTA is a monodentate ligand, it can form up to 4 different species with Cu(I): [Cu(PTA)n]+ 
(n = 1–4). Thus, depending on the concentration and Cu(I):PTA stoichiometry, the predominant species 
differs.48,50,51  
In the present work, we report the use of PTA in presence of Zn (and in absence for direct comparison) 
on Cu(I) (and Cu(II)) targeting, removal from Aβ, and consequences on ROS production and Aβ 
aggregation, the two key and deleterious events occurring in the amyloid cascade linked to the 
aetiology of AD. This is a proof-of-concept study in the sense that it addresses the possibility to keep 
in the presence of Zn the positive effect of PTA48 against Cu-associated deleterious effects such as ROS 
production and oligomers formation. Nevertheless, other requirements the ligand should also fulfil for 
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further therapeutic purposes such as the capacity to pass through the blood-brain barrier52 or to have 
a good ADME (absorption, distribution, metabolism and excretion) / Toxicity profile53 are not under 
focus. 
Experimental 
Chemicals 
A stock solution of Cu(II) at 20 mM was prepared by dissolving CuSO4·5H2O (Sigma Aldrich) in ultrapure 
water. Similarly, ZnSO4·H2O (from Strem Chemicals) was dissolved in ultrapure water to prepare a 20 
mM stock solution of Zn(II). HEPES buffer was bought from Sigma Aldrich and dissolved in ultrapure 
water to a final concentration of 0.5 M, and pH was adjusted to 7.4 by addition of NaOH. A 0.5 M stock 
solution of Tris-d11 was prepared by dissolving the appropriate amount of the buffer powder (Sigma 
Aldrich) in D2O and adjusting the pH with D2SO4. A stock solution of sodium ascorbate (Sigma Aldrich) 
at 10 mM was daily prepared in ultrapure water. PTA was prepared as previously described in the 
literature.54 A stock solution of Thioflavin T (Acros Organics) at ca. 5 mM was prepared by dissolving 
the powder in ultrapure water, with further titration by UV-vis spectroscopy (ε412-ε500 = 36 000 M-1cm-
1).55 From this stock solution, 250 µM aliquots were prepared and kept at -20 °C until use. All the 
peptides were bought from GeneCust (Dudelange, Luxembourg) with a purity grade > 98 %. Stock 
solutions of human Aβ16 (sequence DAEFRHDSGYEVHHQK) were prepared at ca. 5 mM by dissolving 
the powder in ultrapure water, and their concentration was determined by UV-vis absorption of Tyr10 
considered as free tyrosine (ε276-ε296 = 1410 M-1cm-1). The human Aβ40 peptide (sequence 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) was purified to obtain only a monomeric 
fraction prior its aggregation according to a previously reported protocol.56 The peptide concentration 
was measured by UV-vis absorption of Tyr10 at basic pH (ε293-ε360 = 2400 M-1cm-1). The shorter Aβ16 
peptide has been used for the experiments studying the coordination and the ROS production as a 
valuable model for Cu(II) binding to the full length peptide. The longer Aβ40 peptide has been used for 
the experiments involving aggregation. No differences between the short and full-length hAβ peptides 
have been observed for their binding Cu(II) coordination, binding affinity or ROS production.40,57  
X-Ray Absorption Near Edge Structure (XANES) 
Zn-K edges XANES spectra were recorded on the FAME beamline at the European Synchrotron 
Radiation Facility (ESRF, Grenoble, France) during an 18-shifts session in April 2017 (Experiment 
number 30-02-1125). The measurements were performed on mM solutions at low temperature (He-
cryostat) in the fluorescence mode using a 30-element high-purity Ge detector. The energy was 
calibrated by the measurement of Zn foil spectra in transmission. For each sample, at least 3 XANES 
spectra were recorded and averaged. Samples for XANES measurements were prepared in presence 
of 10% of glycerol as cryoprotectant.  
Nuclear Magnetic Resonance (NMR) 
NMR experiments were performed on an Avance 600 Bruker NMR spectrometer. All the 
reactant solutions were prepared in D2O, and pH was adjusted with additions of D2SO4 or NaOD. 
Spectra were recorded at 298 K (for the methylene protons of PTA and its complex) or 318 K 
(aromatic protons of the peptide and its complexes). 318 K was chosen in order to obtain well 
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resolved peaks of the aromatic protons of the peptide. On the other hand, temperature was 
decreased for the spectra of the methylene protons of PTA since at 318 K the AB system of the 
NCH2N protons was hindered by the signal of water.   
UV-vis spectroscopy 
UV-vis spectra were recorded on an Agilent 8453 UV-visible spectrometer, equipped with a Peltier 
temperature controller unit which maintained the solution temperature at 25 °C. For the kinetics of 
Cu(II) removal from the CuII,Zn(Aβ16) complex by PTA, the full spectra from 250 to 900 nm were 
recorded to study both the influence on the Tyr10 absorption band (280 nm) and the Cu(II) d-d band 
at 620 nm.  
Ascorbate consumption 
The spectra of consumption of ascorbate, which mirror the production of ROS,37 were obtained by 
measuring the absorbance of ascorbate at 265 nm (ε = 14 500 M-1cm-1) with a correction at 800 nm as 
a function of time. 
Figure 2. 1H-NMR spectra at selected regions: panel A, aromatic region of a) Aβ16, b) Zn(Aβ16) complex, c) CuII,ZnII(Aβ16) + 6 equivalent of PTA; panel B, methylene 
protons of a) PTA, b) Cu(II) + 6 equivalents of PTA, c) CuII,ZnII(Aβ16) + 6 equivalents of PTA. Conditions: [Aβ16] = 300 µM, [Zn(II)] = [Cu(II)] = 270 µM, [PTA] = 1.8 
mM, [Tris-d11] = 50 mM, pH = 7.4, T = 318 K (A) and 298 K (B).
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Thioflavin T assay 
Kinetics of aggregation by the Thioflavin T (ThT) assay were recorded using a FLUOstar OPTIMA (BMG 
Labtech) plate reader. The experiments were prepared in 384-wells non-binding plates (Greiner 
BioOne) by dissolving the appropriate quantities of each reactant, in presence of ThT at 10 µM. 0.1 µM 
of EDTA was added (i.e.: 0.5% of [Aβ40]) to sequestrate trace metal ions. We have control that EDTA 
has no effect on the aggregation of the Aβ peptide. ThT was excited at 440 nm and the emission was 
set at 490 nm. Three independent experiments were performed with three replicates for each 
condition.  
Transmission Electron Microscopy (TEM) 
Samples were taken after aggregation for 72 hours in the 384-well plates and collected by same 
conditions criteria. They were prepared for electron microscopy by using the conventional negative 
staining procedure. An aliquot (20 µL) of solution was absorbed on Formvar-carbon-coated grids for 2 
min, blotted, and negatively stained with uranyl acetate (1%) for 1 min. Grids were examined with a 
TEM (Jeol JEM-1400, JEOL Inc, Pea- body, MA, USA) at 80 kV. Images were acquired by using a digital 
camera (Gatan Orius, Gatan Inc, Pleasanton, CA, USA) at 4000 or 25000 magnifications. 
Results and discussion 
Zn binding to PTA 
XANES (X-ray Absorption Near Edge Structure) measurements were carried out to study the possible 
formation of a Zn(II)-PTA complex since it is the most suitable spectroscopic technique for Zn(II) which, 
due to its d10 electronic configuration, remains silent in most classical techniques. The complex 
[ZnCl2(PTA)2] had already been isolated by Smolenski et al.58 as an air-stable solid product which 
undergoes ligand displacement in water. The formation of a Zn(II)-PTA complex is not observed in 
aqueous solution, as confirmed by XANES data (figure S1, a and b): the XANES spectrum of Zn(II) in 
buffer + 5 equivalents of PTA (b in figure S1) is virtually the same as Zn(II) in buffer (a in figure S1) at 
mM concentrations, thus indicating a very low affinity, at least lower than 103 M-1, of PTA for Zn(II). 
This is the reason why PTA cannot compete with the peptide Aβ for binding Zn(II) (c in figure S1).  
PTA keeps its ability to reduce and remove Cu from Aβ even in the presence of Zn(II) 
The ability of PTA to reduce and remove Cu(II) from the Aβ peptide has been previously shown.48 In 
this work, its ability has been tested also in the presence of Zn(II) which, as  previously seen, can be 
found in the brain at higher concentration than copper. The very low affinity of PTA for Zn(II) leads to 
a good Cu-over-Zn selectivity overcoming that of Aβ as confirmed by 1H-NMR spectroscopy (figure 2). 
Once PTA is added to a preformed solution of CuII,ZnII(Aβ), the ligand targets Cu(II) specifically to 
reduce it to Cu(I) and remove it from the peptide. In this process, Zn(II) remains bound to Aβ as it can 
be observed in figure 2, A: the aromatic protons of the peptide, and more specifically the histidine 
protons, recover the shift of the Zn(Aβ) complex after addition of 6 equivalents of PTA to the 
heteronuclear CuII,ZnII(Aβ). The formation of the [Cu(PTA)4]+ complex is confirmed by the downfield 
shift of the AB system of the NCH2N protons of PTA (from 4.47 to 4.51) and the PCH2N protons (from 
a defined doublet at 3.90 for uncoordinated PTA to a broad singlet at 4.01 for the [Cu(PTA)4]+ 
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complex).48,59 PTA oxide is formed as a by-product of the reduction of Cu(II) to Cu(I)48 and it can be 
observed in the spectra of the reactions Cu(II) + 6 equiv. of PTA (b in figure 2B) and CuII,ZnII(Aβ) + 6 
equiv. of PTA (c in figure 2B). The AB system of PTA oxide is centred at 4.23, while the PCH2N protons 
appear as a doublet at 3.95.  
The low affinity of PTA for Zn(II) confers this ligand a very good Cu-over-Zn selectivity, overcoming that 
of Aβ. Indeed, the presence of Zn(II) does not impede PTA to reduce Cu(II) bound to the peptide and 
remove it to form the [Cu(PTA)4]+ complex, leaving Zn(II) still coordinated to Aβ (Scheme 1). 
The rate of Cu(II) to Cu(I) reduction by PTA in presence or absence of Zn(II) has also been studied by 
following the Cu(II)-characteristic d-d band at 620 nm (figure 3, A). This study also allows the 
monitoring of the time needed to reduce copper and if the addition of zinc alters the kinetic of the 
reduction. Data obtained were fitted to an exponential decay function characteristic of first-order 
reactions (equation 1).  
 
  
 
Figure 3. A) UV-Vis absorption spectra following the reduction of Cu(II) to Cu(I) by recording the Cu(II) d-d band over 5.5 h. Cu,Zn(Aβ16), dark blue line; Cu,Zn(Aβ16) 
+ 5 equiv. PTA from 0 h (blue line) to 5.5 h (green line), measured every 120 s (0 → 2040 s) or 600 s (2040 → 20040 s). Conditions: [Cu(II)] = 90 μM, [Aβ16] = 100 
μM, [Zn(II)] = 90 μM, [PTA] = 500 μM, [HEPES] = 50 mM, pH 7.4. B) kinetic of the decrease of the maximum corresponding to the d-d band of the CuII(Aβ16) (at 
630 nm, blue dots) of CuII,Zn(Aβ16) (at 620 nm, orange dots) complexes. Raw data of the absorbance from the UV-Vis spectra (left panel) have been averaged 
around the wavelength corresponding to the maximum of absorbance to eliminate noise due to the very low absorbance intensity. Data have been fitted to an 
exponential decay function (CuII(Aβ16 : blue line and Cu,Zn(Aβ16) : orange line). 
Scheme 1. Summary of the reactions taking place with Cu and Zn complexes with the Aβ peptide with or without PTA.
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Equation 1. Exponential decay function where x = time (s), y = normalized absorption max (a. u.) and k = reduction rate constant (s-1). 
In presence of Zn(II) the reduction of Cu(II) to Cu(I) is slightly slower: k(-)Zn = 2.0 x 10-4 s-1 vs. k(+)Zn = 1.7 
x 10-4 s-1 (figure 3, B) in line with the displacement of Cu(II) to its coordination mode II (figure 1) in the 
heteronuclear complex CuII,ZnII(Aβ),7,37,38,60 which is expected to be more difficult to reduce. 
Nevertheless, this slightly slower rate does not hamper the overall reduction and removal of copper 
process. Indeed, after fours hours and in presence of 5 equivalents of PTA at [Cu(II)] = 90 µM (Figure 
3, B), most of Cu(II) is reduced regardless the presence of zinc (Scheme 1). PTA has a higher selectivity 
for copper over zinc than Aβ as demonstrated by these results. Therefore, the presence of Zn(II) in 
solution does not prevent PTA from reducing Cu(II) to Cu(I) and subtracting it from the peptide. 
The presence of Zn(II) does not impact the formation of [Cu(PTA)4]+ in a ROS-forming reaction 
Then, the effect of PTA on ROS production by Cu(Aβ) was probed in absence and presence of Zn(II). 
The redox activity of the mono- and dinuclear peptide complexes was followed by the consumption of 
ascorbate, which is a biologically relevant reductant. Monitoring of the ascorbate consumption at 265 
nm mirrors the production of ROS because ascorbate performs the reduction of Cu(Aβ) that, in turn, 
reduces O2 to O2•-, H2O2 and HO•.19 The mixed-metal complex has indeed a slightly higher ascorbate 
oxidation rate than the monometallic complex Cu(Aβ) (figure 4) as already reported.61 In this case, 
regardless the presence of Zn(II) and its enhancement for ROS production, 5 equiv. of PTA do 
effectively arrest the ROS production by Cu bound to Aβ (Figure 4 and Scheme 1).  
PTA can prevent Cu-induced oligomerisation of the Aβ peptide even in the presence of Zn(II) 
PTA previously showed to be effective avoiding the formation of Cu(Aβ) oligomers and restoring the 
formation of apo-like amyloid fibrils.48 In this work, its ability has been also tested in presence of Zn(Aβ) 
and the heteronuclear complex Cu,Zn(Aβ). First, the impact of 5 and 20 equivalents of PTA on Cu(Aβ) 
aggregation were evaluated (Figure 5, panel A and Figure S2, panel A). Under the conditions used in 
the present study apo-Aβ exhibits a sigmoid-like curve in the ThT fluorescence experiment, where ThT 
Figure 4.UV-Vis absorption of ascorbate (followed at λmax = 265 nm) as a function of time in presence of Cu(Aβ16) (blue 
dots) and Cu,Zn(Aβ16) (orange dots) and after addition of 5 equivalents of PTA. Conditions: [Cu(II)] = [Zn(II)] = 10 µM, 
[Aβ16] = 12 µM, [PTA] = 60 µM, [ascorbate] = 100 µM, [HEPES] = 50 mM, pH 7.4, T = 25 °C.
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is a dye that acquires a strong fluorescence upon interaction with β-sheets structures, thus mirroring 
the formation of β-sheets.62  In the presence of up to 0.9 equiv. of Cu(II), the sigmoid-like curve is 
conserved but the start of the aggregation is delayed and the intensity reached at the plateau is ca. 
half of that observed for the apo-fibrils. This is in line with the aggregates observed by TEM (Fig. S3), 
since shorter fibres are formed and in less quantity. Addition of 20 equivalents of PTA leads to the 
recovery of the sigmoid curve and morphology of the apo-peptide fibrils. This recovery is only partial 
in the case of addition of 5 equivalents of PTA (Fig. S2 & S3) due to the partial oxidation of PTA to 
overcome the reoxidation of Cu(II) when there is not enough reductant in the medium. This is in line 
with what was observed and discussed in our previous work.48 Furthermore, consistent with the low 
affinity of PTA for Zn(II), the addition of PTA to the Zn(Aβ40) solution does not change either the 
aggregation curve nor the aggregates formed: indeed, in presence of 0.9 equivalents of Zn(II), with or 
without PTA, an initial acceleration of the aggregation process is observed and after less than 12 hours 
a plateau is reached, of approximately 35% of the intensity of the apo-peptide (Fig. 5, panel B). 
Furthermore, the morphology of the aggregates formed in presence of Zn(II) could be described as 
amorphous aggregates (Fig. S3) in line with previous reports.13,63,64 When the aggregation experiment 
is run in presence of 0.9 equivalents of both Cu(II) and Zn(II), a similar curve to that observed for the 
Zn(Aβ40) complex is obtained but with a lower final intensity (Fig. 4, panel C). The morphology of the 
aggregates relates as well to the Zn(II) complex (Fig. S3). In accordance to literature,18 Zn(II) dominates 
the aggregation process but the presence of Cu(II) leads to lower intensity ThT signal. Addition of 20 
equivalents of PTA leads to a ThT-curve and TEM images which are very similar to those of the Zn(Aβ40) 
complex. Therefore, the presence of Zn(II) does not preclude the removal of Cu(II) from the peptide by 
PTA and its addition could prevent the formation of more toxic aggregates such as Cu-induced 
oligomers. Contrary to what is observed after the addition of only 5 equivalents of PTA to the Cu(Aβ) 
complex, 5 equivalents are enough to sequestrate Cu(II) from Aβ when in presence of Zn(II) and obtain 
a curve similar to that of the Zn(Aβ) complex (Fig. S2). We anticipate that the formation of insoluble 
Zn(Aβ) aggregates facilitates the formation of the redox silent [Cu(PTA)4]+ complex in solution. In brief, 
the presence of Zn does not preclude the removal of Cu(II) from Aβ by the PTA ligand and induces the 
formation of Zn-type aggregates. 
Figure 5. ThT-fluorescence spectra as a function of time of the aggregation of Aβ40 in presence of (A) Cu(II), (B) Zn(II) and (C) Cu(II) + Zn(II); and the effect of 
adding 20 equivalents of PTA. [Aβ40] = 20 μM, [Cu(II)] = [Zn(II)] = 18 μM, [PTA] = 400 μM, [ThT] = 10 μM, [NaCl] = 100 mM, [EDTA] = 0.1 μM, [HEPES] = 50 mM, 
pH 7.4, T = 37 °C. Colour code of curves: (A) a) grey, apo-Aβ; b) blue, Cu(Aβ); c) green, Cu(Aβ) + PTA; (B) d) grey, apo-Aβ; e) orange, Zn(Aβ); f) green, Zn(Aβ) + 
PTA; (C) g) orange, Zn(Aβ); h) purple, Cu,Zn(Aβ); i) green, Cu,Zn(Aβ) + PTA.
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Discussion and concluding remarks 
As noted in the Introduction, the speciation of the [Cu(PTA)n]+ complex changes depending on the 
Cu:PTA stoichiometry, the concentration and the other molecules present in the reaction medium. In 
the conditions of the experiments described in this work, both [Cu(PTA)2]+ and [Cu(PTA)3]+ have been 
proposed to be predominant in solution.48,50,51 Quaretti et al.51 hypothesised that, in presence of Aβ, 
the prevalence of the [Cu(PTA)2]+ species could lead to the formation of ternary species such as 
[Cu(PTA)2(Aβ)], in line with the ternary complexes formed with PTA and the aromatic bidentate ligands 
BCA (2,2’-biquinoline-4,4’-carboxylic acid) and i-BCS (bathocuproinedisulfonic acid). Contrary to this 
theory, the NMR spectra shown here, together with the XANES spectra previously reported,48 do not 
show the formation of a ternary Cu(I)-Aβ-(PTA)2 species. This may be due to the linear binding mode 
of Cu(I) by the Aβ peptide that would not easily accommodate the tetrahedral geometry of such 
ternary species, in contrast to what is observed with the BCS or BCA ligands.51    
To sum up, we show in this work how PTA maintains its effectiveness to remove Cu ions from the Aβ 
peptide even in the presence of highly-concentrated Zn(II). In fact, a Cu-over-Zn selectivity greater than 
that of Aβ should be one of the required characteristics for metal-targeting ligands as potential drug 
candidates in the treatment of AD as previously demonstrated for Cu(II).7 The here described proof-
of-concept idea could be a key point to overcome the failure of metal-targeting molecules in clinical 
trials of AD. As presented in the introduction, a soft base atom such as P in the case of PTA, will show 
a greater affinity for Cu(I) than for Zn(II) satisfying the Cu-over-Zn selectivity criteria. Therefore, playing 
with the electronic properties of the ligand might be enough for Cu(I)-targeting ligands, while other 
structural parameters should be considered as well for Cu(II)-targeting ligands. This will be of 
importance when translating these requirements into drugs with potential clinical use due to the 
complexity of the biological environment. 
Another interesting point is that Ceresa et al.66 have demonstrated that the anti-cancerous 
[Cu(PTA)4]PF6 complex is not neurotoxic at concentrations higher than its IC50 value in human cancer 
cells. In addition, the complex can enter neurons without exerting any in vivo deleterious effects.66 This 
could be interesting to restore a normal homeostasis of copper in the brain, another key point when 
developing therapeutic metal-targeting drugs aimed at restoring normal Cu homeostasis in the 
brain.67,68 
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